Work Area: Valuation

Latest content

BlackBerry patent sale almost there but still not over the line

“We are literally down to the last few important items now,” says company CEO John Chen on Q3 earnings call

22 December 2021

It’s a big 48 hours for BlackBerry and the patent market in general

The company is due to release its Q3 financials tomorrow, but it is not known whether the touted sale of a portfolio of well over 30,000 individual assets will also be announced

20 December 2021

IAM insight panel analysis Q4 2021

Featured in Community Insight

The president’s choice for director of the agency sees uptick in positive sentiment towards the administration’s policies in the survey findings for IAM’s Q4 Panel Report

09 December 2021

Australia under-invests in IP, and recent government proposals will not fix that

Saturday Opinion: In-house leaders say a mooted patent box regime limited to life sciences will reward companies that get patents already, failing to encourage IP investment in new industries

04 December 2021

Why patent litigators are now central to a wide range of commercial disputes

The Long Read: It’s no longer all about infringement, write Michelle Avery, Nicole McTernan and Drew Sills of Ocean Tomo. Instead, IP specialists are increasingly being called on in a diverse array of corporate lawsuits

01 December 2021

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin

The deal shows how privacy and silo barriers to the commercialisation of information are being overcome

29 November 2021

The IP story to engage the c-suite is there, but it takes bravery to tell it

Saturday Opinion: After a highly successful IPBC in Seattle earlier this week, it is clear that there has never been a better time to take the value creation gospel to the boardroom

20 November 2021

How Aon helps lenders and borrowers manage risk in IP-backed deals

Brian Hinman, chief commercial officer at Aon IP Solutions, tells IAM how the group facilitates IP-backed funding deals centred on high-quality assets

18 November 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum

05 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Unlock unlimited access to all IAM content